The Royal Pharmaceutical Society of Great Britain has welcomed the Centre for Reform's report, Online pharmacy: patient choice or patient peril, and warns that people are dicing with danger if they use
Drug company Pfizer says it is all set to launch a patient-monitoring scheme in order to assess the safety of its novel inhaled-insulin drug Exubera, if the product is approved for use.Exubera
Sweden approves innovative treatment to reduce phosphate risk in patients with end stage renal failure; now FOSRENOL to enter EU mutual recognition procedureSweden's MPA has today granted the first regulatory approval in the world for FOSRENOL (l
Vical Incorporated today announced plans to develop and evaluate electroporation-enhanced delivery of therapeutic and preventive DNA vaccines against HIV under a Cooperative Research and Development Agr
GenoMed, Inc. has announced that it will be limiting its treatment for West Nile virus encephalitis to immunocompetent patients only, where it has posted a 100% success rate. Ten out of ten patients, includi
Helix BioPharma today announced that it has received approval from Sweden's drug regulatory authority, the Medical Products Agency (MPA), to conduct a Phase II clinical trial of Topical Interfe
A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at
Two papers published on September 13 in PLoS Medicine raise concerns about whether world leaders are getting good advice on how best to fund the development and delivery of new vaccines.
Research regarding the illicit use of prescription drugs in the Northern Territory and how this compares to other Australian states is the focus of the next presentation of Charles Darwin University's Faculty of Educa
Acknowledging AstraZeneca's hugely successful hormonal breast cancer therapy, anastrozole (Arimidex), Frost & Sullivan presented the company w
Based on the FDA's assessment of currently available data, including the lack of survival benefit in the Phase III Trial 709 (ISEL) comparing Iressa to placebo in advanced recurrent non-small-cell lung cancer (NSCLC), and the availability of other treatment options in the United States that do prolong life, the revised label indicates that Iressa is only to be used in patients who have previously taken Iressa and are benefiting or have benefited from Iressa. In addition, Iressa will continue to be available for use in clinical trials approved by an Institutional Review Board (IRB) prior to June 17, 2005. Clinical trials approved by an IRB after June 17, 2005, must be conducted under an investigational new drug application (IND).
To implement the new label, as of September 15, 2005, AstraZeneca will initiate the Iressa Access Program to fill renewal prescriptions for Iressa through a single mail order pharmacy for patients meeting the criteria set forth by the label. Iressa will remain available in the United States, through the Iressa Access Program, for patients who are currently benefiting or who have benefited, pending availability of new data that would support an additional revision to the label, or possible future withdrawal. Approximately 4,000 patients currently are taking Iressa in the United States.
"AstraZeneca and the FDA have worked diligently to ensure uninterrupted access for existing patients in the United States who are benefiting from Iressa. Current patients should be assured that their access to Iressa will continue with this program," said Dr. Judith Ochs, oncologist and Senior Medical Director for Iressa in the United States. "The label change now clarifies which patients the FDA believes should receive this drug and the Iressa Access Program ensures that only those patients will be able to get the medication."
Patients taking Iressa as of September 15, 2005 may continue to receive Iressa and will fill prescription refills through the Iressa Access Program after required patient and physician forms are filed. After September 15, 2005, no new patients will be allowed access to Iressa unless they are part of a clinical study approved by an IRB prior to June 17, 2005 or they are part of a clinical study approved by an IRB after June 17, 2005 that is conducted under an IND. The updated label and information on the Iressa Access Program, including enrollment forms, are available by calling AstraZeneca at 1-800-601-8933 or via the web at http://www.iressa-access.com/
Iressa is approved in the United States under accelerated approval by the FDA (sub-part H) that enabled the drug to be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product had an effect on a surrogate end point likely to predict clinical benefit in a serious or life threatening illness for which there is an unmet medical need. The Phase III study called ISEL, or trial 709, released in December showed that Iressa did not produce a statistically significant survival advantage over placebo in patients with advanced NSCLC.
AstraZeneca is continuing to evaluate potential predictive biomarkers to better identify more readily those patients who are most likely to benefit from Iressa. AstraZeneca is committed to continuing Iressa research and to validating the emerging science in controlled clinical trials.
http://www.astrazeneca.com/